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Apolipoprotein E (ApoE) is a major constituent of many lipoprotein particles. Previous genetic studies have focused
on six genotypes defined by three alleles, denoted e2, e3, and e4, encoded by two variable exonic sites that segregate
in most populations. We have reported studies of the distribution of alleles of 20 biallelic variable sites in the gene
encoding the ApoE molecule within and among samples, ascertained without regard to health, from each of three
populations: African Americans from Jackson, Miss.; Europeans from North Karelia, Finland; and non-Hispanic
European Americans from Rochester, Minn. Here we ask (1) how much variation in blood levels of ApoE (lnApoE),
of total cholesterol (TC), of high-density lipoprotein cholesterol (HDL-C), and of triglyceride (lnTG) is statistically
explained by variation among APOE genotypes defined by the e2, e3, and e4 alleles; (2) how much additional
variation in these traits is explained by genotypes defined by combining the two variable sites that define these
three alleles with one or more additional variable sites; and (3) what are the locations and relative allele frequencies
of the sites that define multisite genotypes that significantly improve the statistical explanation of variation beyond
that provided by the genotypes defined by the e2, e3, and e4 alleles, separately for each of the six gender-population
strata. This study establishes that the use of only genotypes defined by the e2, e3, and e4 alleles gives an incomplete
picture of the contribution that the variation in the APOE gene makes to the statistical explanation of interindividual
variation in blood measurements of lipid metabolism. The addition of variable sites to the genotype definition
significantly improved the ability to explain variation in lnApoE and in TC and resulted in the explanation of
variation in HDL-C and in lnTG. The combination of additional sites that explained the greatest amount of trait
variation was different for different traits and varied among the six gender-population strata. The role that noncoding
variable sites play in the explanation of pleiotropic effects on different measures of lipid metabolism reveals that
both regulatory and structural functional variation in the APOE gene influences measures of lipid metabolism. This
study demonstrates that resequencing of the complete gene in a sample of 20 individuals and an evaluation of
all combinations of the identified variable sites, separately for each population and interacting environmental context,
may be necessary to fully characterize the impact that a gene has on variation in related traits of a metabolic system.
Introduction
Apolipoprotein E (ApoE) is an integral surface com-
ponent of triglyceride (TG)–rich chylomicrons, chylo-
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micron remnants, very-low-density lipoprotein (VLDL),
and high-density lipoprotein (HDL) and is involved in
the receptor-mediated metabolism of these particles
(Davignon et al. 1988; Mahley 1988; Davignon 1993;
Mahley and Rall 2000). The ApoE molecule has three
common isoforms—E2, E3, and E4—that can be iden-
tified by PAGE (Utermann et al. 1977). The observed
variation in the isoelectric points of these isoforms is
attributable to cysteine-arginine variation at positions
112 and 158 in the 299-amino-acid chain of the ApoE
molecule. These two variations are encoded by variable
sites in exon 4 (positions 3937 and 4075; fig. 1) of the
APOE gene (MIM 107741), which is located on chro-
mosome 19q13. Combinations of variations at these two
Figure 1 Genomic structure and locations of SNPs in APOE, for each population stratum
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variable sites define three alleles—denoted “e2,” “e3,”
and “e4,”—that encode the three common isoforms. The
designations are historical, and the fourth possible com-
bination of these two biallelic sites has not been
observed.
Association studies, which have focused mainly on
quantitative blood measures of lipid metabolism, have
estimated that, in the population at large, ∼12%–20%
of the interindividual variation in the ApoE level, as
well as 5%–8% of the interindividual variation in total
cholesterol (TC) level, is associated with variation
among the six genotypes defined by the e2, e3, and e4
alleles (Sing and Davignon 1985; Boerwinkle and Uter-
mann 1988; Davignon et al. 1988; Kaprio et al. 1991;
Xhignesse et al. 1991). Furthermore, individuals with
the e4 allele are reported to suffer cardiovascular dis-
eases (CVD) more often than do individuals without
this allele (Davignon et al. 1988; Kuusi et al. 1989;
Davignon 1993; Wald et al. 1994; Stenga˚rd et al. 1995).
More recently, the six APOE genotypes have been
shown to also influence interindividual variation in both
the risk of Alzheimer’s disease (Corder et al. 1993; Mah-
ley and Huang 1999) and the progression of neurolog-
ical disease in those infected with HIV (Corder et al.
1998). There is also evidence that the six APOE ge-
notypes influence interindividual variation in TG and/
or HDL cholesterol (HDL-C) levels in some strata (Nel-
son et al. 2001; Lussier-Cacan et al. 2002).
In a recent study that resequenced 5.5 kb of the
APOE gene, including related 5′- and 3′-flanking
regions, we identified 21 variable sites in a sample of
72 unrelated individuals, composed of 24 individuals
from each of three populations: Jackson, Miss.; North
Karelia, Finland; and Rochester, Minn. (Fullerton et al.
2000; Nickerson et al. 2000) (fig. 1). Twenty of the
observed sites are biallelic single-nucleotide polymor-
phisms (SNPs), and one site varied for a multiallelic
insertion/deletion polymorphism (site 5229a) and a SNP
(site 5229b). Variation at site 5229 was not measured
for the study reported here because the nested nature
of variation at this site rendered high-throughput SNP
genotyping impractical. Of the 21 SNPs, 17 are located
in noncoding regions (i.e., are noncoding SNPs [non-
cSNPs]), and 4 are located in a coding region (i.e., are
coding SNPs [cSNPs]). In addition to the two cSNPs in
exon 4 that encode the three common isoforms, a third
cSNP is located between these two (position 4036; fig.
1), and the fourth cSNP is located in exon 3 (position
3106; fig. 1). Variations in each of the four cSNPs result
in amino acid changes. Of the 20 SNPs included in the
study reported here, 16 were variable in the Jackson
sample, 14 were variable in the North Karelia sample,
and 13 were variable in the Rochester sample. The 10
that varied in all three samples included the two cSNPs
that encode the three common ApoE isoforms. This ob-
servation is consistent with previous studies that have
established that the e2, e3, and e4 alleles are found in
most populations (Davignon et al. 1988; Hallman et al.
1991; Gerdes et al. 1992; Stenga˚rd et al. 1998).
The availability of 18 additional APOE SNPs leads
to the question of whether the measurement of one or
more of these additional SNPs can improve our ability
to statistically explain interindividual variation in quan-
titative measures of lipid metabolism—and ultimately
to explain variation in the risk for CVD. To address
this question in the present article, we ask the following,
for each gender, in samples from each of three popu-
lations: (1) How much trait variation is associated with
variation among the genotypes defined by the e2, e3,
and e4 alleles encoded by the 3937 and 4075 cSNPs?
(2) How much additional trait variation is associated
with genotypes defined by the combination of the 3937
and 4075 cSNPs with one or more additional SNPs? (3)
What are the locations and the relative allele frequencies
of the sites in the subset of sites that combine with sites
3937 and 4075 to significantly improve the statistical
explanation of trait variation?
Material and Methods
Samples
The Jackson sample included 702 unrelated African
Americans (483 females and 219 males) who were
45–64 years of age. The participants were measured for
fasting (12 h) blood levels of ApoE, of TC, of HDL-C,
and of TG, and samples were genotyped for all of the
16 APOE SNPs that were found to segregate in Jackson
(Fullerton et al. 2000). Participants were examined ac-
cording to a standardized protocol and were part of the
ongoing GENOA study, which was designed to identify
and characterize genes that influence the risk for essential
hypertension (FBPP Investigators 2002). For the mea-
surements of weight and height, participants wore light-
weight clothing and removed their shoes.
The North Karelia sample included 337 unrelated
Europeans (188 females and 149 males) who were
45–64 years of age. The participants were measured for
blood levels of TC, of HDL-C, and of TG, and samples
were genotyped for all of the 14 APOE SNPs that were
found to segregate in North Karelia (Fullerton et al.
2000). A subsample of 162 females and 124 males were
measured for ApoE level. In connection with an ongo-
ing prospective study (the population-based FINRISK
study), participants were examined, between 11:00 A.M.
and 6:00 P.M., according to a standardized protocol (Sal-
omaa et al. 1994; Vartiainen et al. 1994), which was
designed to evaluate the utility of established risk factors
as predictors of CVD in middle-aged female and male
Finns. Participants were told to avoid fatty meals and
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to fast for 4 h prior to the examination and blood
sampling. The length of fast and the type of previous
meal were recorded. The initial analysis of these re-
cordings indicated good compliance with the instruc-
tions (Salomaa et al. 1994). For the measurements of
weight and height, participants wore lightweight cloth-
ing and removed their shoes.
The Rochester sample included 854 unrelated non-
Hispanic European Americans (456 females and 398
males) who were 45–64 years of age and who were from
the middle generation of 583 three-generation pedigrees
that were recruited, between December 1984 and July
1991, by the Rochester Family Heart Study. These ped-
igrees were ascertained through school-age children, re-
gardless of the health status of the children, parents, or
grandparents (Moll et al. 1986; Turner et al. 1989). Par-
ticipants were measured for fasting (12 h) blood levels
of ApoE, of TC, of HDL-C, and of TG, and samples
were genotyped for all of the 13 APOE SNPs that were
found to segregate in Rochester (Fullerton et al. 2000).
For the measurements of weight and height, participants
wore lightweight clothing and removed their shoes.
Laboratory Methods
Quantitative measures of blood-lipid and ApoE levels
for the Jackson and Rochester samples were taken at
the Mayo Clinic (Rochester, MN), by published methods
(National Institutes of Health 1974; Barr et al. 1981;
Kaprio et al. 1991). Those for the Finnish sample were
measured at the Department of Biochemistry, National
Public Health Institute, Helsinki, by standard enzymatic
assays (Boehringer Mannheim Diagnostics) (Salomaa et
al. 1994; Schiele et al. 2000). The methods used to ge-
notype the APOE SNPs have been described by Nick-
erson et al. (2000).
Statistical Methods
In all three samples, the distributions of levels of ApoE
and TG were significantly positively skewed in both gen-
ders. The natural log (ln) transformation of these vari-
ables reduced skewness to nonsignificant values !0.5 in
each case. These transformed variables were used in the
analyses presented here to accommodate statistical tests
that assume normality.
We used Fisher’s F ratio, to test whether there was a
statistically significant difference, between female and
male participants, in the phenotypic variance of a trait
(Sokal and Rohlf 1995). Student’s t test was used to test
the statistical significance of the difference between gen-
der means when the F ratio was not significant, and
Satterthwaite’s modification of the t test (Sokal and
Rohlf 1995) was used when the F ratio was significant.
Permutation tests were also done to assess statistical sig-
nificance (details are given below).
The Boerwinkle and Sing (1986) bias-corrected esti-
mator of genetic variance, , was used to measure the2jG
utility, for the statistical explanation of phenotypic var-
iability, of different sets of multisite genotypes. It esti-
mates the component of a trait’s phenotypic variance,
in the population at large, that is attributable to devi-
ations of genotype means from the population mean,
weighted by the relative frequencies of the genotypes.
The estimator is as follows:
2 2— — —
k k n( ) ( )in Y  Y Y  Yi i ij ik 12S p  G n n n kip1 ip1 jp1
SS k 1Gp  MS ,Wn n
where n is the total sample size, k is the observed number
of genotype classes, is the sample grand mean, ni is
—
Y
the number of individuals with the ith genotype class,
is the sample mean of the ith genotype, Yij is the
—
Yi
phenotype of the jth individual in the ith genotype class,
and MSW is the mean-squared estimate of the phenotypic
variability among individuals within genotype classes in
the population at large. This statistic adjusts the geno-
typic sum of squares, SSG, from the one-way analysis of
variance by a quantity that increases with the number
of genotypes if the estimate of the mean square within
genotypes, MSW, does not decrease as additional geno-
types are considered.
Permutation methods (Fisher 1935; Lehmann 1986;
Edgington 1995; Good 2000) were used (1) to test the
statistical significance of variation among genotype-class
means ( ) and (2) to test whether the addition2H :j p 0o G
of one or more SNPs to the definition of genotype clas-
ses, beyond the two cSNPs (3937 and 4075) that define
the e2, e3, and e4 alleles, significantly increases in2jG
the gender-specific population being sampled. To test
whether is significantly greater than 0, we generated2jG
a null distribution of 1,000 values from 1,000 sam-2SG
ples, each of which was obtained by randomly reassign-
ing the observed phenotypes to individuals without re-
placement. The null hypothesis is rejected for an a-test
criterion if the original value obtained from the non-2SG
permuted sample exceeds the value associated with2SG
the upper a percentage of the distribution of values ob-
tained from the 1,000 permutations (Good 2000). We
considered 1,000 permuted samples because it has been
suggested that this number is sufficient to give a stable
estimate of the critical value for an a-test criterion (Chur-
chill and Doerge 1994).
To test whether the addition of sites significantly in-
creased the estimate, we computed the difference,2jG
, between the value associated with the variation2 2DS SG G
in the six APOE genotypes defined by the 3937 and
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Table 2
Statistically Significant Estimates of Percent Trait Variation Explained by Two-Site APOE Genotypes and by the Best Sets of Three-Site
and Multisite APOE Genotypes
TWO-SITE
GENOTYPES
BEST SET
OF THREE-SITE GENOTYPES
BEST SET
OF MULTISITE GENOTYPES
Estimate A
(% variance) nG
a
Estimate B
(% variance) Added SNP nG
a
Test of
Improvement,b
B vs. A
Estimate C
(% variance) nG
a
Test of
Improvement,c
C vs. B
Jackson, Miss., sample:
Female participants ( ):Np 483
lnTG … … 4.3** 560 17 9.8** 111 *
HDL-C … … 3.0** 624 12 8.3** 77 *
TC 4.0*** 6 4.9*** 1163 10 9.1* 94
lnApoE 15.5*** 6 19.3*** 4036 7 *** 23.0*** 112
Male participants ( ):Np 219
lnTG … … … … … … 12.1* 56
HDL-C … … … … … … 9.9* 26
TC 3.2* 6 7.9** 560 13 ** 15.4** 38 *
lnApoE 14.6*** 6 24.6*** 4036 9 *** 30.2*** 37 *
North Karelia, Finland, sample:
Female participants ( d):Np 188
lnTG … … … … … … … … …
HDL-C … … 5.5* 560 11 15.3*** 38 **
TC 4.3* 6 4.3* 1575 7 6.0* 15
lnApoE 11.1*** 6 13.9*** 2440 11 * 23.4*** 31 *
Male participants ( e):Np 149
lnTG … … 4.2* 1575 6 8.2* 28
HDL-C … … … … … … … … …
TC 5.3* 5 6.7* 560 10 14.5** 29 *
lnApoE 8.8** 5 17.2*** 1575 6 *** 24.9*** 23
Rochester, Minn., sample:
Female participants ( ):Np 456
lnTG … … … … … … … … …
HDL-C … … 2.6* 560 14 … … …
TC 3.2** 6 3.9** 5361 10 7.7* 82
lnApoE 20.0*** 6 20.4*** 2907 8 20.8*** 51
Male participants ( ):Np 398
lnTG … … … … … … 3.5* 28
HDL-C … … … … … … … … …
TC 2.6** 6 3.5* 624 13 5.9* 38
lnApoE 12.7*** 6 16.3*** 832 14 23.3*** 39 **
NOTE.—The two-site genotypes are defined by sites 3937 and 4075; the three-site genotypes are defined by the combination of sites 3937 and
4075 with one additional site; and the multisite genotypes are defined by the combination of sites 3937 and 4075 with multiple additional sites.
* .a  0.05
** .a  0.01
*** .a  0.001
a Number of observed genotypes.
b The best three-site genotype model is compared to the two-site genotype model defined by only the 3937 and 4075 cSNPs, if both explained
a statistically significant amount of interindividual trait variation.
c The best statistically significant multisite genotype model (“Estimate C”) is compared to the best statistically significant three-site genotype
model (“Estimate B”).
d For lnApoE, .Np 162
e For lnApoE, .Np 124
4075 cSNPs and the value associated with the ge-2SG
notypes defined by the array of SNPs being considered
(which always included the 3937 and 4075 cSNPs). The
null hypothesis (i.e., ) of no improvement2H :Dj p 0o G
in the estimate was rejected for an a-test criterion if2jG
the original value obtained from the nonpermuted2DSG
sample exceeded the value associated with the upper2DSG
a percentage of the distribution of values obtained from
1,000 permuted samples. Each permuted sample was
created by the random shuffling of the observed phe-
notypes among genotypic classes within each of the six
APOE genotype classes defined by the 3937 and 4075
sites. The expected value is influenced by (1) the2DSG
separate marginal effects of the genotypes defined by
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additional SNPs and (2) statistical interactions between
the effects associated with the genotypes defined by the
added SNPs and the effects associated with the six ge-
notypes defined by sites 3937 and 4075. Rejection of
the null hypothesis indicates that the genotypes defined
by the additional SNPs have marginal effects that are
independent of the effects of the six genotypes and/or
the effects of genotypes defined by the additional SNPs
are heterogeneous among the APOE genotypes. It is not
possible to distinguish between these two possibilities
when there is linkage disequilibrium between one or
more of the additional sites and site 3937 and/or site
4075. Unless denoted otherwise, we considered the 0.05
level of probability as the criterion for significance of a
test statistic.
Results
Gender-Specific Distributions of Quantitative Measures
of Body Size and Lipid Metabolism
A description of the female and male samples from
each of the three populations is given in table 1. Within
each of the three populations sampled, the age distri-
butions and at least two of the three anthropometric
characteristics—height, weight, and/or BMI (in kg/
m2)—were significantly different between female and
male participants. Similarly, the distributions of at least
two of the four quantitative measures of lipid metabo-
lism were significantly different, between genders, within
each of the three samples. These observations are con-
sistent with widely recognized gender and ethnic differ-
ences that document the rationale for stratified analyses
of the contribution that genetic variability makes to in-
terindividual variation in trait variability presented be-
low, in which the strata are defined by gender and pop-
ulation sampled.
Population-Specific Distributions of the Relative Allele
Frequencies
The relative frequency of the least common allele at
a variable site ranged from 0.004 to 0.484 (fig. 1). Five
of the 20 SNPs had an extremely rare allele. Their rel-
ative frequencies were !0.01, and they segregated in only
one (Jackson [at site 545] and North Karelia [at sites
1522 and 1575]) or two (North Karelia and Rochester
[at sites 2907 and 3106]) samples. One of the cSNPs
(site 3937) involved in the definition of the e2, e3, and
e4 alleles is in the middle of the distribution of relative
frequencies in all three populations (ranges between
0.139 and 0.225), whereas the other (site 4075) is in the
lower tail of this distribution (ranges between 0.039 and
0.103). The relative frequencies of the least common
allele for the other two cSNPs (site 4036 in the Jackson
sample and site 3106 in the North Karelia and Rochester
samples) were also in the lower tail of the distribution.
Two of the non-cSNPs (site 832 in the promoter region
and intronic site 2440) have the most common alleles
in all three samples. Common allelic variations were also
observed in promoter-region sites 560 and 624 and in-
tronic sites 1163 and 1998, in all three samples.
Relative allele frequencies were significantly different
( ) among samples for all but two sites, 2907P ! 0.05
and 3106 (fig. 1). The largest interpopulation difference
in the relative frequency of the least common allele is
seen at site 5361, where it ranges from 0.182 (in the
North Karelia sample) to 0.014 (in the Jackson sample).
The smallest interpopulation difference is seen at site
2440, where the relative frequency of the least common
allele ranges from 0.360 (in the Jackson sample) to 0.482
(in the North Karelia sample). The interpopulation dif-
ferences in the relative frequency of the common allele
at sites 3937 and 4075 are between these two ex-
tremes—ranging, respectively, from 0.225 and 0.103 (in
the Jackson sample) to 0.139 and 0.093 (in the Roch-
ester sample) and 0.223 and 0.039 (in the North Karelia
sample). The observed population differentiation of al-
lele frequencies further justifies stratified analyses of the
contribution that genetic variability makes to the statis-
tical explanation of interindividual trait variability pre-
sented below (see “Contribution of the APOE Geno-
types Defined by the 3937 and 4075 cSNPs to a
Statistical Explanation of Interindividual Variation in
Quantitative Measures of Lipid Metabolism in Each
Gender-Population Stratum”), where strata are defined
by the populations sampled.
Contribution of the APOE Genotypes Defined
by the 3937 and 4075 cSNPs to a Statistical
Explanation of Interindividual Variation
in Quantitative Measures of Lipid Metabolism
in Each Gender-Population Stratum
The estimates of the amount of interindividual vari-
ation in lnApoE and TC levels explained by the two-site
genotype model defined by the combination of the 3937
and 4075 cSNPs were statistically significant in all six
gender-population strata (table 2, under “Estimate A”).
In female participants, 11%–20% of the variation in
lnApoE, as well as 3%–4% of the variation in TC level,
was explained by variability among the genotypes de-
fined by these two cSNPs. In male participants, estimates
ranged from 9% to 15% of variation in lnApoE and
from 3% to 5% of variation in TC. Genotypes defined
by the 3937 and 4075 cSNPs did not explain a significant
amount of interindividual variation in HDL-C or lnTG,
in any of the gender-population strata.
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Consequences of Combining One SNP with the 3937
and 4075 cSNPs for Statistically Explaining
Interindividual Variation in Quantitative Measures of
Lipid Metabolism in Each Gender-Population Stratum
For each trait in each gender-population stratum, we
determined the sets of three-site genotypes (defined by
the combination of one additional SNP with the 3937
and 4075 cSNPs) that explained the greatest amount of
trait variation and that were statistically significant.
These sets are presented in table 2, under “Estimate B.”
In the Jackson sample, two different SNPs combine
with the 3937 and 4075 cSNPs to define three-site ge-
notypes (table 2, under “Estimate B”) that explained
significantly larger proportions of interindividual vari-
ation in lnApoE and TC than the APOE genotypes en-
coded by the 3937 and 4075 cSNPs (table 2, under “Es-
timate A”). One set, defined by the 3937, 4036, and
4075 cSNPs, improved the statistical explanation of
lnApoE variation in both female (19% vs. 16%) and
male (25% vs. 15%) participants. A second set of ge-
notypes, defined by the combination of site 560 with the
3937 and 4075 cSNPs, improved the statistical expla-
nation of TC variation in male (8% vs. 3%) participants.
In addition, we found that, in female participants, the
combination of sites 560 or 624 with the 3937 and 4075
cSNPs explained a significant amount of lnTG (4%) and
HDL-C (3%) variation, respectively, whereas the ge-
notypes defined by sites 3937 and 4075 did not.
In the North Karelia sample, two different SNPs com-
bined with the 3937 and 4075 cSNPs to define three-
site genotypes that gave a significant improvement in the
statistical explanation of variation in lnApoE when com-
pared to the genotypes defined by the 3937 and 4075
cSNPs. The set defined by the addition of site 2440 im-
proved the statistical explanation of lnApoE variation
in female (14% vs. 11%) participants, whereas the set
defined by the addition of site 1575 improved the ex-
planation of lnApoE variation in male (17% vs. 9%)
participants. None of the sets of three-site genotypes
provided statistically significant improvement in the ex-
planation of variation in TC in either gender. In addition,
we found that the combination of site 560 with the 3937
and 4075 cSNPs significantly explained 6% of HDL-C
variation in females and that the combination of site
1575 with these two-sites significantly explained 4% of
lnTG variation in male participants, whereas the ge-
notypes defined by sites 3937 and 4075 did not statis-
tically explain variation in either case.
In the Rochester sample, none of the sites in combi-
nation with sites 3937 and 4075 defined three-site ge-
notypes that explained significantly larger proportions
of interindividual variation in lnApoE or TC in either
gender than did the APOE genotypes encoded by sites
3937 and 4075. In female participants, we found that
genotypes defined by the combination of site 560 with
the 3937 and 4075 cSNPs explained a significant frac-
tion (3%) of HDL-C variation, whereas the genotypes
defined by sites 3937 and 4075 did not.
Consequences of Combining Two or More SNPs with
the 3937 and 4075 cSNPs for Statistically Explaining
Interindividual Variation in Quantitative Measures of
Lipid Metabolism in Each Gender-Population Stratum
The best sets of multisite genotypes defined by the
combination of sites with the 3937 and 4075 cSNPs that
explained a statistically significant amount of trait var-
iation are given, in table 2 (under “Estimate C”), for
each trait in each gender-population stratum. The site
that was combined with the 3937 and 4075 cSNPs to
define the best set of three-site genotypes that explained
a statistically significant amount of trait variation (table
2, under “Estimate B”) was always found to be included
in the set of sites that were combined with the 3937 and
4075 cSNPs to define the best multisite genotype model
that explained a significant amount of trait variation
(figs. 2A and 2B).
In the Jackson sample, there was no statistically sig-
nificant evidence that the addition of sites beyond those
included in the best three-site model improves the ex-
planation of lnApoE or TC (table 2, under “Test of
Improvement, C vs. B”) in female participants. In male
participants, two different additional sets of sites defined
multisite genotypes that explained significantly more
variation in lnApoE or TC than the best three-site com-
binations did (fig. 2B). The magnitude of improvement
in the explanation of the lnApoE variation by the first
set of multisite genotypes was modest (30% vs. 25%),
whereas the amount of TC variation that was explained
by a second set (15%) was almost twice the amount
explained by the best set of three-site genotypes (8%).
In female participants, there was one set of multisite
genotypes that explained significantly more variation in
lnTG, as well as another set that explained significantly
more variation in HDL-C (fig. 2A), than that obtained
using the best sets of three-site genotypes. Furthermore,
in male participants, we found one set of multisite ge-
notypes that significantly explained 12% of variation in
lnTG and a second set that significantly explained 10%
of variation in HDL-C (fig. 2B), whereas neither the
APOE genotypes defined by sites 3937 and 4075 nor
any of the three-site genotypes defined by the combi-
nation of a site with the 3937 and 4075 cSNPs explained
a significant amount of variation.
In the North Karelia sample, one set of multisite ge-
notypes significantly improved the explanation of vari-
ation in lnApoE in female participants (23% vs. 14%),
and a second set of multisite genotypes significantly im-
proved the explanation of TC variation in male partic-
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ipants (15% vs. 7%). A third set of multisite genotypes
gave a significant improvement in the explanation of
HDL-C variation in females compared to the best set of
three-site genotypes (15% vs. 6%). No combination of
sites explained a significant amount of variation in ei-
ther HDL-C, in male participants, or lnTG, in female
participants.
In the Rochester sample, none of the sets of multisite
genotypes significantly improved the explanation of trait
variation in female participants. One multisite combi-
nation significantly improved the explanation of lnApoE
variation in male participants. Furthermore, we found
a set of multisite genotypes that significantly explained
4% of lnTG variation in male participants, whereas nei-
ther theAPOE genotypes defined by sites 3937 and 4075
nor any of the three-site genotypes defined by the com-
bination of a site with the 3937 and 4075 cSNPs ex-
plained a significant amount of variation.
Discussion
One promise of the postgenomic era is that fast and
inexpensive gene-measurement technologies will em-
power medical and public health care delivery systems
to incorporate variation at the DNA level into algo-
rithms for the identification of individuals and popula-
tions that are at increased risk for common chronic dis-
eases that have a complex multifactorial etiology (Sing
et al. 1996). At present, the widely accepted research
strategy for the evaluation of the utility that DNA in-
formation has in risk assessment considers only one or
two variable sites in each candidate gene. In line with
this research strategy, nearly all earlier studies of the
APOE gene have considered only the two cSNPs (3937
and 4075) that encode nonsynonymous amino acid
changes that were discovered as a consequence of the
characterization of electrophoretic variations of the gene
product. This top-down strategy is the typical approach
for the selection of measures of gene variation. It uses
prior knowledge about the biology of intermediate bi-
ochemical and physiological traits that connect genome
variation with variation in the risk for disease. Variations
are selected because they change the amino acid sequence
or because they mark an established promoter region.
Such a top-down strategy de-emphasizes the study of the
possible pleiotropic effects of the gene and ignores the
fact that phenotypic effects of each variable DNA site
are contingent on the context defined by other variable
sites in the gene and interacting agents, including other
genes and exposures to environments both internal and
external to the organism. Furthermore, the impact that
heterogeneity has, among populations, in both the struc-
ture of gene variation (wherein it is defined by the num-
ber of alleles and the relative allele and genotype fre-
quencies) and genetic architecture (wherein it is defined
by the contribution that variations in the gene make to
trait variation) cannot be evaluated unless all variable
sites within the gene are considered. Hence, to obtain a
comprehensive, bottom-up evaluation of the contribu-
tion that variation in a candidate gene makes to variation
in intermediate biochemical and physiological traits—
and, ultimately, to risk for disease—the contribution of
genotypes determined by all known variable sites must
be evaluated in samples that are representative of the
interacting environmental contexts and populations of
interest. To do otherwise requires assumptions about
gene variation and homogeneity of gene effects that are
likely to be false and that cannot be tested.
Our expectation that noncoding variable sites, in dif-
ferent combinations with variation at sites 3937 and
4075, will have utility in the explanation of phenotypic
variation in different contexts defined by gender and
population was the motivation for the study reported
here. This bottom-up strategy for the evaluation of the
contributions of additional variable DNA sites began
with the resequencing of a sample of individuals ascer-
tained without regard to health, to characterize the var-
iation in the APOE gene in each population. We then
asked whether we can statistically explain significantly
greater variation in measures of lipid metabolism in
samples of six gender-population strata by combining
variation at the 3937 and 4075 sites with 1 or more of
the 18 additional SNPs revealed by the initial resequ-
encing step. Our study suggests that the commonly held
assumptions, which are based on studies of variation in
sites 3937 and 4075, that APOE gene variation and the
connection between this variation and phenotypic var-
iation in measures of lipid metabolism are homogeneous
among populations should be questioned.
The Role of Gender and Population Structure
in the Definition of the Population of Inference
Ignoring the gene variations that do not vary in all
populations can result in the definition of a population
of inference that is not representative of any population.
Studies that pool female and male data and data from
different populations assume that genotype-phenotype
relationships are independent of context indexed by gen-
der and population. Both the heterogeneity observed in
the trait distribution between genders within samples
from a particular population and among samples from
different populations for a particular gender and the
heterogeneity of relative allele frequencies among sam-
ples from different populations suggest that an analysis
of pooled data will produce inferences that are not rep-
resentative of either gender or of any population. Het-
erogeneity of genetic structure, defined by relative allele
and genotype frequencies, is of particular concern be-
cause the contribution that variation in a gene makes to
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Figure 2 Combinations of variable sites that define the best sets of genotypes—requiring the inclusion of the 3937 and 4075 cSNPs—
that explain a statistically significant amount of trait variation, for each of the four lipid traits among females (A) and males (B) from each
population stratum.
the genetic architecture of a quantitative trait (Boerwin-
kle et al. 1986) is determined by deviations of genotype
means from the population mean, weighted by the rel-
ative frequencies of the genotypes. Obviously, the six
sites (four of which are 5′ to the first exon) that vary
only in the Jackson sample cannot make a contribution
to the statistical explanation of trait variation in the
other two samples. Only half of the 20 SNPs that we
studied were variable in all three samples. In all of these
10 cases, relative allele frequencies were significantly dif-
ferent among samples—the maximum difference being
0.24 (at site 832, when Jackson and Rochester samples
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are compared). These differences in the organization of
genetic variation document that these three populations
have very different demographic histories (Fullerton et
al. 2000). Such heterogeneity in the genetic structure of
variation in the gene of interest, as well as in other un-
measured interacting genes, could lead to very different
contributions that a gene makes to the genetic architec-
ture of phenotypic variation in different populations.
The implications of microdifferentiation of relative al-
lele frequencies for the evaluation of the impact that gene
variation has on phenotypic variation in human popu-
lations have been largely ignored because most candi-
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date-gene studies assume that only the public polymor-
phisms (i.e., those that vary in all populations) are
relevant for the prediction of phenotypic variability in
any population (Reich et al. 2001). By using only com-
mon public variations (i.e., those that have an ancient
common ancestor), one assumes that the DNA varia-
tions of recent origin, which vary only in particular pop-
ulations, are of little importance in the determination of
phenotypic variation. The potential bias in the evalua-
tion of the influence that the APOE gene has on phe-
notypic variation could be major, because only half of
the variable sites were found to segregate in all three
samples. Unless all variations, common and rare, are
measured, it is not possible to evaluate the consequences
of the bias associated with this assumption. Our study
documents that this bias can be large. For instance, by
consideration of the rare allele (relative frequency 0.018;
at site 4036), which varies only in the Jackson sample,
it is possible to statistically explain 25% and 68% more
lnApoE variation in female and male participants, re-
spectively, than is explained by genotypes defined by the
e2, e3, and e4 alleles that occur in all three samples. The
significant contribution that a rare variation at site 1575
(which does not vary in the participants from Jackson)
makes to lnApoE and lnTG variation in male partici-
pants from North Karelia (table 2, under “Estimate B”)
serves as a second example.
Experimentwise Error Rate
Our general, global null hypothesis is that none of the
sets of multi-SNP genotypes defined by combining one
or more additional SNPs with the 3937 and 4075 cSNPs
statistically explain a greater proportion of quantitative
variation in any of the four measures of lipid metabolism
than the proportion that is explained by the genotypes
defined by sites 3937 and 4075, in any of the six gender-
population samples. The construction of a null distri-
bution for this hypothesis is complicated by the differ-
ences across samples from different populations, dis-
cussed above (see “The Role of Gender and Population
Structure in the Definition of the Population of Infer-
ence”), in both trait distributions and relative allele fre-
quencies, and by the expected gender-specific differences
among populations in correlations between traits. Fur-
thermore, the fact that different subsets of the APOE
SNPs segregate in different samples dictates that we can-
not exhaustively evaluate the utility of all possible sets
of multi-SNP genotypes across the strata defined by pop-
ulation. There will always be sets that could explain trait
variation only within a particular population. To our
knowledge, when these complications hold, there are no
appropriate statistical methods, traditional or otherwise,
for the testing of the global null hypothesis against the
alternative hypothesis that there is at least one multi-
SNP combination that improves the statistical expla-
nation of trait variation in at least one of the six strata.
In the absence of replicate samples of the many popu-
lations of inference represented here, an alternative
approach—which does not consider a specific statistical
model or the heterogeneity in statistical power, to reject
the null hypothesis across strata and traits—is the cal-
culation of the probability that the observed significance
tests are randomly distributed among the six strata for
each trait. Under the assumption of a 0.05 test criterion
and equal statistical power among tests, for the three
SNP genotype analyses, this probability is !0.01. Given
that, in many of the individual tests, the probability was
!0.05 and given the observation that in no case did
combining a SNP with the 3937 and 4075 cSNPs im-
prove the statistical explanations of variation in any of
the traits in either gender in the Rochester sample
(whereas the analyses of the Jackson and North Karelia
samples resulted in significant improvements in several
comparisons, in both female and male participants), this
probability is likely much smaller. Actually, in the Jack-
son sample, combining a SNP with the 3937 and 4075
cSNPs, to define the best set of three-SNP genotypes,
improved the statistical explanation of lnApoE varia-
tion, in 5,000 permutations in both genders, at P !
, which is less than the Bonferroni0.0002 P ! 0.0005
criteria associated with 100 tests. Furthermore, the ad-
ditional SNPs that defined the best sets (for explanation
of variation) of three-SNP genotypes are not randomly
distributed across the resequenced region of the gene,
but cluster in the 5′ regulatory region. Hence, we feel
confident in rejecting the global null hypothesis in favor
of the alternative hypothesis that there is at least one set
of multi-SNP genotypes that statistically explain varia-
tion in at least one trait, in at least one strata, better
than do the genotypes defined by sites 3097 and 4075.
The distribution among gender-population strata of the
significant tests of the improvement in the explanation
of variation by use of the best combination of all sites
with the 3937 and 4075 cSNPs compared to the best
combination of three-site genotypes was very similar to
the distribution of the significant three-SNP genotype
results. In most cases, the combination of sites with the
3937 and 4075 cSNPs significantly improved the statis-
tical explanation of trait variability only in the samples
from Jackson and North Karelia. We expect that a rep-
lication of our analysis in longitudinal follow-up studies
in progress will help to serve as further evidence for or
against these conclusions.
Contribution of APOE SNPs to the Genetic
Architecture of Measures of Lipid Metabolism
Seventeen years ago, Sing and Davignon (1985) re-
ported the first estimates of the contribution that the
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two variable sites in exon 4 that determine the e2, e3,
and e4 alleles make to interindividual variation in mea-
sures of lipid metabolism in the population at large.
Since that time, hundreds of studies have established that
these three alleles vary in most populations (Gerdes et
al. 1992), and the six genotypes they define explain a
statistically significant fraction of interindividual varia-
tion in lipid and lipoprotein levels (Hallman et al. 1991;
Kaprio et al. 1991; Xhingnesse et al. 1991). The present
study establishes that these two cSNPs do not capture
all of the genetic variation, in APOE, that influences
variation in measures of lipid metabolism. Generally, the
addition of sites resulted in improved statistical expla-
nations of variation for every trait in at least one gender-
population stratum. Two- and three-fold increases were
observed in many cases.
Different regions of the gene statistically explain var-
iation in different components of lipid metabolism. It is
of great importance to note that the identification and
characterization of pleiotropic effects that the APOE
gene has on measures of lipid metabolism depend on the
measurement of non-cSNP variations. The genotypes de-
fined by only the 3937 and 4075 cSNPs explain signif-
icant amounts of variation in lnApoE and TC (figs. 2A
and 2B) but not in HDL-C and lnTG. This result is
consistent with findings of studies that have measured
only the e2, e3, and e4 alleles (Breslow 2000). The pres-
ent study suggests that the addition of genotype varia-
tion defined by the 5′ region of the gene measured by
sites 560 and 624 results in a statistically significant
explanation of 3%–5% of variation in HDL-C in each
of the three female samples. This pleiotropic effect of
the APOE gene is supported by a significant ( )P ! 0.05
marginal effect of either site 560 or the closely linked
624 regulatory site, in each case (Stenga˚rd et al. 2000).
These effects are of the same magnitude as the influence
that variation in sites 3937 and 4075 has on the expla-
nation of variation in TC. The addition of non-cSNP
sites also resulted in the definition of genotypes that
explained statistically significant amounts of variation
in lnTG in particular strata. These results suggest that
the nonstructural, quantitative variations in the APOE
gene product may influence the levels of HDL-C and
TG. Furthermore, measuring only cSNPs, a strategy ad-
vocated by some investigators, would miss as much as
50% of the variation in ApoE.
The observation that the SNPs that confer additional
information about the tendency that interindividual dif-
ferences in lipid metabolism have to cluster in the reg-
ulatory region is consistent with recent laboratory ob-
servations (Artiga et al. 1998a, 1998b), as well as with
our earlier observation that variation in these sites is
involved in the separation, undetected by protein-level
variation, of phylogenetically distinct lineages, or clades,
of the APOE gene tree (Fullerton et al. 2000). Artiga et
al. (1998a, 1998b) have found that sites 560 and 624
combine to define three different haplotypes that have
different transcriptional activities in cell cultures, owing
to their different affinity for nuclear proteins. Both of
these sites, together with sites 832, 1163, and 2440,
define the four most common haplotypes that carry the
e3 allele (Fullerton et al. 2000). The difference, between
populations, in the relative frequencies of these four hap-
lotypes may explain why different combinations of these
SNPs define multisite genotypes that best explain vari-
ations in different traits in different population strata.
The observation that site 560 is seen more often in these
combinations than are the other SNPs may be attrib-
utable to its position in the APOE gene tree, which sug-
gests that it may be particularly susceptible to recurrent
mutations and/or gene conversions, placing it in asso-
ciation with different allelic background, with different
functional effect, in different populations. An analysis
of the effects that the APOE haplotypes have on mea-
sures of lipid metabolism are in progress (A. R. Tem-
pleton, personal communication).
Pleiotropic effects that theAPOE gene has on multiple
traits in the same metabolic system suggest a complex
cause-and-effect genotype-phenotype relationship me-
diated by posttranslational modifications in the gene
product. The observation that such effects occur pri-
marily in female participants further supports the role
that unmeasured interacting agents play in the deter-
mination of a complex, context-dependent connection
between variation in the APOE gene and interindividual
variation in components of the lipid-metabolism system.
These results clearly establish that a top-down strategy
that selects variable DNA sites because they influence
protein sequence (the cSNPs) can underestimate the role
of the gene and miss pleiotropic effects on traits that are
influenced by variation in non-cSNPs.
The present study clearly establishes that it takes more
than one additional site, beyond sites 3937 and 4075,
to capture the contribution that the APOE gene makes
to the variation in the ApoE levels in the Jackson and
North Karelia female and male samples. Furthermore,
the present study also suggests that there may be no
single best set of sites that captures the variation in a
gene that influences variation in a particular trait, in all
samples from different gender-population strata. Even
though the maximum amount of ApoE and TC variation
explained by the combination of multiple sites with the
3937 and 4075 cSNPs is approximately the same
(20%–25% and 6%–10%, respectively) across gender-
population strata, different combinations of additional
sites are involved (figs. 2A and 2B). The differences in
sites selected to explain trait variation is a consequence
of heterogeneity in the structure of gene variation among
populations complemented by heterogeneity in the ge-
notype-phenotype relationships attributable to interac-
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tions with environments internal and external to the or-
ganism indexed by gender and population. Gender and
population are representative of only two of the many
strata that may index such interacting environments. In-
ferences about the utility of any particular SNP—or of
combination of SNPs in risk assessment—therefore need
to be made with caution because (1) rare allele, haplo-
type, or genotype variations with large effects can ex-
plain variation in only a subset of populations (Weiss
and Clark 2002); (2) the effect that a particular SNP has
on trait variation may be conditional on the genotype
of another SNP(s) either in the APOE gene (Hamon et
al. 2001) or in another linked or unlinked gene (Tem-
pleton 2000; Nelson et al. 2001); (3) the genetic archi-
tecture of trait variability may depend on the synergistic
effects, of a combination of SNPs (that each may not
have separate marginal effects), that will be different in
different populations (Hamon et al. 2001); and (4) there
are gene# environment interactions whereby the influ-
ence that a SNP has on phenotype level varies among
environments (Reilly et al. 1992, 1994; Stenga˚rd et al.
1999, 2001; Humphries et al. 2001; Lussier-Cacan et al.
2002). These considerations prompt studies in progress
to ask whether there can be invariant criteria for the
selection of variable sites in candidate-gene studies.
Utility of Genetic Information in Clinical Practice
and Prevention Programs
An ultimate goal of human genetic studies is to pro-
vide information that improves our ability to identify
individuals who have—or are at increased risk for—a
particular disease. Advanced gene-measurement tech-
nologies have made an invaluable contribution to the
identification and characterization of genetic variations
that are involved in the determination of monogenic dis-
eases that are inherited in a Mendelian manner, as well
as to the identification of individuals who carry such
variations (Guo and Lange 2000). In contrast, use of
such technologies for the identification of individuals
who are at increased risk for CVD or other common
chronic diseases has been less successful. The fact that
a DNA sequence variation in a particular gene can be
related to variation in a risk-factor trait and/or in the
risk for disease in a sample from one population while
other variations of the gene, or variations in other
gene(s) are found to be associated with variation in the
very same traits in other populations has limited the
utility of the identified genetic variations in clinical prac-
tice and public health programs. Furthermore, the fact
that the e2, e3, and e4 alleles of the APOE gene that are
present in most populations (Davignon et al. 1988; Ger-
des et al. 1992; Davignon 1993; Stenga˚rd et al. 1998)
explain only a small fraction of interindividual variation
in intermediate traits that connect genome variation with
variation in onset, in progression, and in severity of dis-
ease also makes them unattractive for clinical and public
health applications. The association between an end-
point phenotype and a predictor is expected to be much
stronger before it is a worthwhile consideration in risk
assessment (Wald et al. 1999).
The present study argues that, for most intermediate
quantitative traits whose phenotypes emerge as a con-
sequence of interactions between many genetic and en-
vironmental factors, it may not be possible to identify
either a particular genetic variant or a particular subset
of variants that are specific and/or sensitive enough for
an identification of individuals who are at increased risk
for common chronic diseases. Different populations or
environmental strata within populations may require a
different set of genetic-risk indicators. Such a conclusion
follows from complexity research that has shown that
it is extremely difficult to explain a detailed outcome of
a highly interactive system in terms of the behavior of
either a particular agent or subsets of agents (Sole´ and
Goodwin 2000)—it may even be theoretically impossible
(Axelrod and Cohen 2000). Despite this expectation,
complexity research suggests that we can learn much
about the functioning of the component interacting
agents and about how to use such information in risk
assessment if we ask nontraditional questions about ge-
notype-phenotype relationships. For example, rather
than asking whether a particular variant site is associated
with trait variation, the research strategy employed in
the present study empowers one to identify several sets
of multi-SNP genotypes of the APOE gene that ex-
plained variations in HDL-C and in TG that could not
be explained by genotypes defined by the e2, e3, and e4
alleles. Furthermore, we found several sets of multi-SNP
genotypes that statistically explained two to three times
more TC and lnApoE variation than these genotypes did.
All of the identified sets were, however, either gender-
specific or population-specific, and, in many cases, they
were both gender-specific and population-specific. These
results clearly argue that there is a need for a shift in
the strategy for the incorporation of genetic variation at
the DNA level into algorithms for the identification of
individuals and populations that are at increased risk
for common chronic diseases that have a complex, mul-
tifactorial etiology. Instead of asking which genetic var-
iants are invariant risk indicators of a given trait in all
populations, we should be asking which genetic variants
are risk indicators of which traits in which populations
and strata within a particular population.
Conclusions
Measuring only cSNPs fails to capture all the variation
in the APOE gene that influences lipid metabolism. Mi-
crodifferentiation of APOE SNP alleles among popu-
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lations limits general inferences that can be made about
the impact that gene variation has on trait variation.
Variation in many sites may explain variation in a par-
ticular trait, and the more variation we measure, the
better we can document the pleiotropic effects that the
APOE gene has on multiple measures of lipid metabo-
lism. Establishing whether there are different sets of sites
that explain variation in different populations and en-
vironment strata will require confirmation in longitu-
dinal follow-up studies and replicate samples of partic-
ular environmental strata of particular populations. The
role that non-cSNPs play in the explanation of pleiotro-
pic effects on HDL-C and TG suggests that the APOE
gene has both regulatory and structural functional ef-
fects on lipid metabolism.
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